Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy

Blood

Volumn 88, Issue 2, 1996, Pages 705-713

  Porter, J B ^a   Abeysinghe, R D ^b   Marshall, L ^b   Hider, R C ^b   Singh, S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; TRANSFERRIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL ARTICLE; FEMALE; HIGH RISK POPULATION; HUMAN; IRON OVERLOAD; IRON TRANSPORT; MALE; PRIORITY JOURNAL; THALASSEMIA; TRANSPORT KINETICS;

EID: 0029978555     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.2.705.bloodjournal882705     Document Type: Article

References (32)

1. Hershko C, Rachmilewitz EA: Non transferrin plasma iron in patients with transfusional iron overload, in Crichton RR (ed): Proteins of Iron Storage and Transport in Biochemistry and Medicine. Amersham, The Netherlands, North Holland, 1975, p 427
2. Hershko C, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: An abnormal serum specific iron fraction of potential toxicity. Br J Haematol 40:255, 1978
3. Anuwatanakulchai M, Pootrakul P, Thuvassethakul P, Wasi P: Non transferrin plasma iron in B thalassaemia/hb E and haemoglobin H disease. Scand J Haematol 32:153, 1984
4. Batey RG, Petit JE, Nicholas AW, Sherlock S, Hoffbrand AV: Hepatic iron clearance from serum in treated hemochromatosis. Gastroenterology 75:856, 1978
5. Gutteridge JMC, Rowley DA, Griffiths E, Haliwell B: Low molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 68:463, 1985
6. Wagstaff M, Peters SW, Jones BM, Jacobs A: Free iron and iron toxicity in iron overload. Br J Haematol 61:566, 1985
7. Singh S, Hider RC, Porter JB: A direct method for quantification of non-transferrin bound iron (NTBPI) Anal Biochem 186:320, 1990
8. Al Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GK, Hoffbrand AV: Efficacy and possible adverse effects of the oral iron chelator. 1,2-Dimethyl-3-hydroxypyrid-4-one (L1) in thalassaemia major. Br J Haematol 82:431, 1992
9. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S: Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dis 21:640, 1993
10. Singh S, Hider RC, Porter JB: Separation and identification of desferrioxamine and its metabolites by high performance liquid chromatography and fast atomic bombardment mass spectrometry: Choice of complexing agent and application to biological fluids. Anal Biochem 187:212, 1990
11. Singh S, Mohammed N, Ackerman R, Porter JB, Hider RC: Quantification of desferrioxamine and its iron chelating metabolites by high performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection. Anal Biochem 203:106, 1992
12. Keberle H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119:758, 1964
13. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JWP: Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 73:402, 1989
14. Higgins T: Novel chromogen for serum iron determinations. Clin Chem 27:1619, 1981
15. Young DS, Pestaner LC, Gibberman V: Effects of drugs on clinical laboratory tests. Clin Chem 21:321D, 1975
16. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, Carlstrom A, Dati F, Ward AM, Svendsen PJ: New international reference preparation for proteins in human serum (RPPHS). Clin Chem 40:934, 1994
17. Zettner A, Mansbach L: Application of atomic absorption spectroscopy in the determination of iron in urine. Am J Clin Pathol 44:517, 1965
18. Wapnick AA, Lynch SR, Charlton RW, Septel HC, Bothwell TH: The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. Br J Haematol 17:563, 1969
19. Nienhuis AW, Peterson DT, Henry W: Chelation Therapy in Chronic Iron Overload, in Zaino EC, Roberts RH (eds): Miami, FL, Symposia Specialists, 1977, p 1
20. Lau S, Sarkar B: Comparative studies of manganese(II), nickel(II), zinc(II), copper(II), cadmium(II) and iron(III) binding components in human cord and adult sera. Can J Biochem Cell Biol 62:449, 1984
21. Stojkovski S, Groumakos W, Sarkar B: Iron(III)-binding polypeptide in human cord and adult serum: Isolation, purification and partial characterisation. Biochim Biophys Acta 1137:155, 1992
22. Hershko C: Non-transferrin plasma iron. Br J Haematol 66:149, 1987
23. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ: Non-transferrin-bound iron in plasma and serum from patients with idiopathic hemochromatosis. J Biol Chem 264:4417, 1989
24. Pootrakul P, Josephson B, Huebers HA, Finch CA: Quantitation of ferritin iron in plasma, and explanation of non transferrin iron. Blood 71:1120, 1978
25. Brissot P, Wright TL, Ma W-L, Weisiger RA: Efficient clearance of non-transferrin-bound iron by rat liver. J Clin Invest 76:1463, 1985
26. Wright TL, Brissot P, Ma W-L, Weisiger RA. Characterisation of NTBPI clearance by rat liver. J Biol Chem 261:10909, 1986
27. Randell EW, Parkes JG, Olivieri NF, Templeton DM: Uptake of non-transferrin iron by both reductive processes is modulated by intracellular iron. J Biol Chem 23:16026, 1994
28. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharcon S, Charoenlarp P, Brittenham G, Pippard MJ, Finch CA: Effect of erythroid hyperplasia on iron balance. Blood 71:1124, 1988
29. Link G, Pinson A, Hershko C: Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 107:147, 1985
30. Olivieri NF, Buncie JR, Chew E, Gallanti T, Harrison RV, Keenan N, Logan W, Michell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Eng J Med 314:869, 1988
31. Hider RC, Epemolu O, Singh S, Porter JB: Iron chelator design. Adv Exp Med Biol 356:343, 1994
32. Hedlund BE, Hallaway PE, Hanson GJ, Kling PJ, Berger AE, Dragsten PR: A novel high molecular weight iron chelator produces prolonged high plasma chelator levels in humans, Beuzard Y, Lubin B, Rosa J (eds): in Sickle Cell Disease and Thalassaemia: New Trends in Therapy. Colloque INSERM 234, 1995, p 383